Valtrex herpes transmission indication
Executive Summary
GlaxoSmithKline's Valtrex (valacyclovir) clears FDA for reduction of the risk of heterosexual transmission of genital herpes when used as a suppressive therapy in combination with safer sex practices. The approval follows the recommendations of the Antiviral Drugs Advisory Committee during a May 14 meeting (1"The Pink Sheet" May 19, 2003, p. 14)...
You may also be interested in...
GSK’s Valtrex Clears FDA Cmte.; Herpes Transmission Endpoints Debated
Clinical studies for genital herpes drugs intended to demonstrate a reduction in disease transmission should include seroconversion as a primary endpoint, FDA's Antiviral Drugs Advisory Committee agreed May 14
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.